Welcome to our dedicated page for KESTRA MEDICAL TECHNOLOGIES, LTD. SEC filings (Ticker: KMTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on KESTRA MEDICAL TECHNOLOGIES, LTD.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into KESTRA MEDICAL TECHNOLOGIES, LTD.'s regulatory disclosures and financial reporting.
Kestra Medical Technologies reported strong growth for its third fiscal quarter ended January 31, 2026. Revenue reached $24.6 million, up 63% from the prior-year period, driven by higher ASSURE system prescriptions, market share gains and a richer mix of in-network patients.
Gross margin improved to 52.6% from 43.4%, but GAAP net loss widened to $34.2 million from $21.8 million as operating expenses rose with commercial expansion and public company costs. Adjusted EBITDA loss was $21.2 million. Cash and cash equivalents were $291 million as of January 31, 2026, reflecting proceeds from a 6.9 million-share equity offering. The company raised its fiscal 2026 revenue guidance to $93 million, implying 55% growth versus fiscal 2025.
Reilly Kevin C reported acquisition or exercise transactions in this Form 4 filing.
Kestra Medical Technologies director Kevin C. Reilly received an equity award of 8,300 common shares in the form of restricted stock units. The RSUs were granted at no cash cost and each unit represents one common share. All 8,300 RSUs will vest on September 4, 2026, if he continues serving through that date, at which point he would hold 8,300 vested common shares from this award.
Kestra Medical Technologies director and officer Brian Daniel Webster sold a total of 15,000 Common Shares of KMTS in open-market transactions on February 17, 2026. The sales occurred under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025.
The transactions were executed in three tranches: 11,635 shares at a weighted average price of $25.3937, 3,272 shares at $26.2947, and 93 shares at $27.1789. After these sales, Webster directly held 379,786 Common Shares.
Bain Charger Holdings, L.P., an affiliate of Bain Capital, reports a significant ownership position in Kestra Medical Technologies, Ltd. common shares. As of the close of business on December 31, 2025, Bain Charger directly held 25,172,338 common shares.
These holdings represent approximately 43.1% of Kestra’s outstanding common shares, based on 58,349,053 shares outstanding as of December 5, 2025, as cited from Kestra’s Form 10-Q. Bain Charger and its general partner share voting and dispositive power over these shares.
Kestra Medical Technologies shareholder Brian Webster has filed a Form 144 notice to sell 15,000 common shares. The proposed sale is through Merrill Lynch on NASDAQ, with an aggregate market value of $384,020.06, and an approximate sale date of February 17, 2026.
The 15,000 shares were acquired on March 7, 2025 via a restricted share issuance granted under the issuer’s equity compensation plan. Over the past three months, Webster sold 15,000 common shares on December 29, 2025 for $398,847.04 and another 15,000 shares on January 15, 2026 for $342,023.69.
Endeavour Medtech Growth II LP, Endeavour Medtech Growth II Parallel LP, and Endeavour Medtech II GP Limited report beneficial ownership of 2,448,942 Kestra Medical Technologies common shares, representing 4.20% of the class.
The filing explains that 2,405,643 shares are held by Endeavour Medtech Growth II LP and 43,299 shares by Endeavour Medtech Growth II Parallel LP, with Endeavour Medtech II GP Limited as general partner for both. All reported shares are subject to shared voting and dispositive power, with no sole voting or dispositive authority. The 4.20% figure is based on 58,349,053 common shares outstanding as of December 5, 2025.
T. Rowe Price Associates, Inc. filed a Schedule 13G reporting a significant passive ownership position in Kestra Medical Technologies common stock. As of 12/31/2025, it reported beneficial ownership of 4,369,429 shares, representing 7.5% of the outstanding common stock.
The firm reports sole voting power over 4,208,056 shares and sole dispositive power over all 4,369,429 shares, with no shared voting or dispositive power. T. Rowe Price certifies the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Kestra, and expressly denies beneficial ownership in a legal-admission sense.
Kestra Medical Technologies president, chief executive officer and director Brian Daniel Webster reported selling 15,000 common shares of KMTS on January 15, 2026. The sale was coded as an open-market sale and was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025, indicating it was scheduled in advance. The shares were sold at a weighted average price of $22.8016, with individual sale prices ranging from $22.2800 to $23.1340. After this transaction, Webster beneficially owns 394,786 common shares, held directly.
This Form 144 notice reports a planned sale of restricted common shares of Kestra Medical Technologies, Ltd. The seller intends to sell 15,000 common shares through Merrill Lynch on the NASDAQ, with an indicated aggregate market value of $342,023.69. The shares form part of a larger base of 58,349,053 common shares outstanding.
The securities were originally acquired on 03/07/2025 as a restricted share issuance from Kestra Medical Technologies, Ltd., granted under the issuer’s equity compensation plan. The notice also shows that Brian Webster sold 15,000 common shares on 12/29/2025 for gross proceeds of $398,847.04. By signing the notice, the seller represents that they are not aware of any undisclosed material adverse information about the company.
Kestra Medical Technologies, Ltd. filed a current report stating that it issued a press release announcing its financial results for the fiscal quarter ended October 31, 2025.
The press release, dated December 11, 2025, is attached as Exhibit 99.1, is incorporated by reference into this report, and is furnished rather than filed, so it is not automatically incorporated into other securities filings unless specifically referenced.